Background Remdesivir is an antiviral medicine approved for the treatment of mild‐to‐
moderate coronavirus disease 2019 (COVID‐19). This led to widespread implementation …

Remdesivir is an antiviral agent that has shown broad‐spectrum activity, including against
severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2). Clinical trials investigating …

Background In view of many unanswered clinical questions regarding treatment of COVID-
19 with remdesivir, we systematically identified, critically appraised and summarized the …

Abstract The coronavirus disease 2019 (COVID-19) pandemic has become a global health
crisis. Considering the recent food and drug administration (FDA) approval of remdesivir as …

Background Remdesivir is considered to be a specific drug for treating coronavirus disease
2019. This systematic review aims to evaluate the clinical efficacy and risk of remdesivir …

Background Efficacy and safety of treatments for hospitalized COVID-19 are uncertain. We
systematically reviewed efficacy and safety of remdesivir for the treatment of COVID-19 …

Purpose: To evaluate the safety and efficacy of remdesivir in adult patients with COVID-19.
Methods: PubMed, Embase, Scopus, Web of Science, Cochrane Library, ClinicalTrials. gov …

Objectives We performed a systematic review and network meta-analysis of randomized
controlled trials (RCTs) to provide updated information regarding the clinical efficacy of …

Background The nucleotide analogue prodrug remdesivir was among the first antiviral
therapies to be tested in randomized controlled trials (RCTs) for COVID-19. We performed a …

Objectives Evaluation of remdesivir, an RNA polymerase inhibitor, for effectiveness in adults
with COVID-19. Data sources Electronic search for eligible articles of PubMed, Cochrane …